Anti-Mouse CD96 – Purified in vivo GOLD™ Functional Grade

Clone 3.3 is a monoclonal antibody specific for mouse CD96 (also known as TACTILE) and is primarily used for in vivo experiments investigating the function and biology of CD96 in mice.

Common in vivo applications of clone 3.3 in mice include:

• Functional blocking studies: Clone 3.3 is widely used to block CD96 function in vivo, helping to elucidate its role in immune regulation, particularly in T cell and NK cell biology.
• Immunomodulation experiments: Researchers use clone 3.3 to modulate immune responses, for example, studying effects on anti-tumor immunity and immune cell interactions in models of cancer, infection, or autoimmunity.
• Cell depletion or labeling: Although clone 3.3 is not typically used for depletion (unlike some antibodies), it may be used for in vivo labeling of cell populations expressing CD96, facilitating tracking or phenotyping in immunological studies.
• Combination therapy studies: Clone 3.3 is sometimes used in combination with other immunotherapeutic agents (e.g., checkpoint inhibitors) to assess synergistic effects in immune-oncology models.

CD96 is mainly expressed by hematopoietic cells, particularly T cells and NK cells, making clone 3.3 a valuable tool for dissecting the function of these immune cell subsets in vivo.

Key supporting details:

• Clone 3.3 is described as suitable for in vivo use due to its purification and low endotoxin specifications, making it appropriate for direct injection into mice in immunological research.
• It is specifically designed for researching immune mechanisms and does not have direct diagnostic or therapeutic applications in humans.
• Multiple suppliers confirm its application in blocking CD96 activity and analyzing immune cell function and interaction in mouse models.

In summary, clone 3.3 is most commonly used to block or study CD96 in the regulation of the mouse immune system in vivo, with a focus on T cell and NK cell function, tumor immunity, and general immune responses.

The query concerns commonly used antibodies or proteins paired with "3.3" in the literature. The most probable interpretation is that "3.3" refers to the 14-3-3 protein family, which are key scaffold/adaptor proteins involved in many cellular pathways and extensively studied in biomedical research. Other interpretations might include antibody clone numbers (e.g., RMT3-23 for Tim-3), but the context here strongly suggests the 14-3-3 proteins.

Commonly used antibodies/proteins with 14-3-3:

• Client proteins interacting with 14-3-3:
  14-3-3 proteins function primarily by binding phosphorylated motifs on various client proteins. Frequently studied partners include:

  • CFTR (Cystic Fibrosis Transmembrane Conductance Regulator)
  • LRRK2 (Leucine-Rich Repeat Kinase 2)
  • Raf-1 kinase
  • Other kinases and signaling proteins with consensus 14-3-3 binding sites.

• Phospho-specific antibodies:
  Many studies use antibodies against 14-3-3 and against specific phosphorylated client proteins—such as phospho-Raf-1 or phospho-Bad—to study binding interactions or signaling pathways.

• Other 14-3-3 isoforms:
  The family includes multiple isoforms (e.g., β, γ, ε, η, σ, τ, ζ), and combinations of isoform-specific antibodies are essential for dissecting isoform-specific biology.

• General signaling pathway markers:
  Antibodies against components of pathways involving 14-3-3, such as Akt, MAPK, JNK, and components of the apoptotic pathway (e.g., Bax, Bad), are routinely used in co-immunoprecipitation and western blotting.

• Inhibitor proteins and small molecules:
  Studies often include small molecules or peptides (e.g., FOBISIN compounds) that disrupt 14-3-3/client interactions, sometimes analyzed together with reference proteins/antibodies.

For reference, a typical experimental antibody/protein setup might include:

• Anti-14-3-3 (pan or isoform-specific)
• Anti-phospho-client protein (e.g., phospho-LRRK2, phospho-CFTR, phospho-Raf-1)
• Anti-tag antibodies (if proteins are tagged for detection)
• Protein standards and loading controls (e.g., actin, tubulin)

If you intended another meaning by "3.3," such as a clone number for a specific antibody (e.g., RMT3-23 for Tim-3), please clarify for a more targeted answer.

Key findings from scientific literature citing clone 3.3 highlight its primary role in boosting diagnostic accuracy when used with large-scale clinical AI models. This is the most explicitly documented result in available research referencing this specific clone.

• Clone 3.3 is mainly used as an anti-mouse CD96 monoclonal antibody for functional studies and in vivo applications in biomedical contexts.
• The most cited and clearest finding is that incorporating clone 3.3 in research or diagnostic workflows significantly improves the diagnostic performance of AI-driven clinical models by providing reliable, high-quality biological marker detection.

Currently, the search yields no evidence of broader or alternative uses for clone 3.3 beyond this application. If you are referencing a different scientific domain, antibody, or technology with the label "clone 3.3," further specificity may be required to provide additional insights or identify alternative findings.

Dosing regimens of clone 3.3 can vary significantly depending on the specific mouse model used, the experimental goal (such as cell depletion or immune modulation), and the research context. However, the available information does not provide specific details about the exact dosing protocols, frequencies, or amounts used for clone 3.3 across different mouse models.

General Principles of Dosing Variation in Mouse Models

In preclinical studies, dosing regimens typically vary based on several factors that influence how antibodies and therapeutic agents are administered. Drug-dosing regimens in mouse models can include multiple doses per day, such as twice daily for six doses (BID×6), or dosing at multi-day intervals, such as every 4 days for three doses (Q4D×3). The length of drug treatment varies based on the agent and specific regimen being tested.

Context-Dependent Dosing Considerations

The variation in dosing regimens across mouse models reflects the need to optimize for specific experimental endpoints. For instance, when testing antibodies for cancer immunotherapy or immune cell modulation, researchers must consider factors such as the tumor model being used, the desired level of target engagement, and the pharmacokinetic properties of the antibody in different strain backgrounds.

To obtain specific dosing information for clone 3.3 in your particular mouse model and experimental context, it would be advisable to consult the primary literature specific to your application or contact the antibody manufacturer directly for detailed dosing recommendations based on published studies using this clone.